Technology | August 27, 2008

Spectranetics Announces First Laser Lead Extraction Procedures in Japan

August 28, 2008 - Spectranetics Corp. today announced the first use in Japan of its Spectranetics Laser Sheath (SLS II) technology for removal of cardiac leads.

The SLS II approval by the Ministry of Health, Labor and Welfare is one of just three medical device technologies chosen annually under a fast track review in Japan. This technology has been used in the U.S. and Europe for more than a decade in over 45,000 successful procedures and is an important tool to manage lead-related issues that may arise in the roughly 4 million pacing and defibrillation leads implanted annually in patients worldwide.

Two procedures were recently performed at Tokyo Women’s Medical University by Dr. Morio Shoda, chief of clinical cardiac electrophysiology and associate professor of cardiology, and Dr. Satoshi Saito, assistant professor of cardiovascular surgery, under the proctorship of Dr. Roger Carrillo, the director of surgical electrophysiology at the University of Miami. Both cases involved leads that were infected, and all leads were successfully removed from the heart and encapsulating scar tissue using the SLS II Laser sheath without complication.

Dr. Shoda commented, “I am very pleased to begin using the SLS II Laser Sheath to remove leads from Japanese patients for whom this form of management is needed. Now in Japan we can safely address the needs of many patients with implantable pacemakers and defibrillators without subjecting them to more invasive surgical procedures.”

“In my years of experience with lead extraction procedures, the laser sheath is an indispensable tool that has helped me remove leads in a very safe, effective and efficient manner in hundreds of patients,” said Dr. Roger Carrillo. “In this first case in Japan, the laser sheath was successful in extracting a chronic lead where all other techniques had previously failed.”

As an escalating number of patients receive implanted cardiac devices, concerns surrounding lead management options have risen. Infection continues to be a primary cause for concern with leads, although lead malfunction and patient lifespan are increasingly causing physicians to consider lead removal versus lead abandonment, the current standard-of-care practice.

The SLS II uses “cool” ultraviolet light to safely, effectively and efficiently ablate scar tissue that holds problematic leads in place. A circle of fibers that emit pulses of energy travels over the cardiac lead to dissolve scar tissue that binds the lead to the body. Once the scar tissue is dissolved, the lead can be safely removed. Spectranetics is also in the process of seeking approval of the Lead Locking Device (LLD) technology in Japan, which can be used to assist removal with the SLS II by transmitting traction on the lead from within its hollow inner structure.

For more information: www.spectranetics.com

Related Content

A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Medtronic Tyrx Envelope Significantly Reduces Major Infections in Cardiac Implantable Device Patients
News | EP Lab | March 20, 2019
Results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) demonstrated...
Videos | EP Lab | February 27, 2019
This is a virtual heart with the same electrophysiology characteristics as the real patient being developed to help o
Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Feature | EP Lab | January 21, 2019 | Matthew S. McKillop, M.D., FACC, FHRS, and Seth J. Worley, M.D.
Interventional...
An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Overlay Init